Bortezomib: a new therapeutic option for POEMS syndrome


Kaygusuz I., Tezcan H., Cetiner M., Kocakaya O., Uzay A. , Bayik M.

EUROPEAN JOURNAL OF HAEMATOLOGY, vol.84, no.2, pp.175-177, 2010 (Journal Indexed in SCI) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 84 Issue: 2
  • Publication Date: 2010
  • Doi Number: 10.1111/j.1600-0609.2009.01341.x
  • Title of Journal : EUROPEAN JOURNAL OF HAEMATOLOGY
  • Page Numbers: pp.175-177
  • Keywords: Bortezomib, POEMS syndrome, polyneuropathy, STEM-CELL TRANSPLANTATION, BEVACIZUMAB THERAPY, PERIPHERAL-BLOOD, PATIENT

Abstract

Objective: POEMS syndrome with its classical five findings (Polyneuropathy, Organomegaly, Endocrinopathy, M protein, and Skin changes) is a rare multisystem disease. Proinflammatory and proangiogenic cytokines play important roles in its pathogenesis. Treatment options are still debated. Methods: We present a 65-year-old man with POEMS syndrome who was successfully treated with bortezomib. Results: After seven cycles of this protocol, serum M protein level declined to normal range, and near-to-complete remission was achieved. His symptoms of polyneuropathy improved dramatically. Conclusion: Bortezomib may be an effective and safe therapeutic option for patients with POEMS syndrome.